This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Therapeutic Protein and Peptide DNA Display Platform
BioVenic provides an in vitro DNA display platform for the discovery and optimization of veterinary therapeutic proteins and peptides, supporting targeted screening of high-affinity ligands for various animal diseases. Our platform covers the complete cell-free selection workflow—custom DNA library construction, streptavidin-fusion peptide synthesis and DNA linkage, conjugate extraction from emulsions, affinity selection against immobilized bait, washing/elution, iterative enrichment rounds, and high-throughput sequencing with data analysis. We support one-stop, tailored discovery programs from consultation and library design through screening, reporting, and after-sales technical support to deliver validated candidate ligands.
DNA Display Platform Overview
DNA display is an advanced cell-free technique in molecular biology for protein and peptide discovery, and it is increasingly used in the development of veterinary therapeutic drugs. It creates a library of DNA sequences, each encoding diverse proteins or peptides, which are lined to their corresponding DNA molecules. Thus, the direct link between the DNA and its encoded proteins or peptides is allowed to select the functional candidates. This method can overcome the technical limitations of conventional display technologies and has proved widely applied to screen diverse libraries of mutant protein and peptide ligands for various target receptors.
Fig.1 The veterinary therapeutic protein and peptide DNA display selection cycle. (BioVenic Original)
DNA Display Services
| Description | Services | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DNA Display Platform Features
- A vast library of DNA sequences encoding a variety of peptides or proteins is created.
- The proteins or peptides are fused to streptavidin, facilitating their subsequent biotin labeling and selection processes.
- Proteins or peptides are biotinylated and linked to their encoding DNA via biotin-streptavidin interaction, forming DNA–peptide conjugates.
BioVenic offers other in vitro platforms to discover therapeutic proteins and peptides, including the ribosomal display, and mRNA display. Please click the following links.
Service Workflow
BioVenic offers comprehensive services for the development of veterinary therapeutic protein and peptide drugs using cutting-edge DNA display technology. This method facilitates the discovery and optimization of high-affinity ligands with significant therapeutic potential in veterinary medicine. Our services include consultation, DNA display library construction, screening, analysis and reporting, and after-sales support. BioVenic also offers a one-stop solution for developing veterinary therapeutic proteins and peptides, ensuring tailored solutions to meet the unique needs of each client through our extensive display services.
Fig.2 The workflow of services for veterinary therapeutic protein and peptide DNA display is illustrated. (BioVenic Original)
Related Research
Addressing the conformational constraints inherent to standard DNA-encoded chemical library (DEL) implementations, Petrov et al. developed a flexibility-tunable, dual-display Encoded Self-Assembling Chemical (ESAC) library of 56 million cyclic peptide macrocycles to systematically map ligand-binding dynamics. The platform utilizes an enhanced Large Encoding Design system to assemble two synthetic sub-libraries at the ends of partially complementary DNA heteroduplexes, splitting complex peptide synthesis across two strands to maximize compound purity. By integrating a two-step cyclization strategy—combining interstrand copper-catalyzed azide-alkyne cycloaddition with cysteine-targeted bis-electrophilic or disulfide crosslinking—the architecture accommodates three distinct levels of spatial constraint: open, semi-closed, and fully closed macrocyclic configurations. Target-directed affinity selections across human alkaline phosphatase, streptavidin, and thrombin revealed that varying conformational flexibility directly dictates binding efficiency, yielding a potent thrombin inhibitor specifically from the rigidified macrocyclic subset. This strategy demonstrates that tuning structural flexibility within dual-display DELs significantly enhances the hit-discovery landscape for target proteins requiring distinct macrocyclic rigidities.
Fig. 4 DP-DEL library architecture and synthesis.1
Why Choose Us?
Fig.3 The advantages of veterinary therapeutic protein and peptide DNA display platform. (BioVenic Original)
Case Study
A company partnered with BioVenic to discover peptide ligands that remain active under elevated temperatures, for improved formulation and storage of a veterinary therapeutic. Because bacterial display limits library diversity and RNA-based tags degrade under stress, we applied its DNA display platform: a randomized DNA library encoding streptavidin-fused peptides was compartmentalized in water-in-oil emulsions, translated in vitro, and linked to its encoding DNA via biotin–streptavidin. Parallel selections were run under standard conditions and under a heat-stress pre-treatment designed to eliminate unstable variants. The standard selection arm rose quickly and plateaued at a high retained fraction by Round 5, while the heat-stress arm remained very low through Rounds 1 and 2, then climbed steadily and overtook the standard arm by Round 5—demonstrating selective enrichment of thermostable binders. High-throughput sequencing confirmed that the heat-stress pool converged on sequence families with stability-related motifs.
Fig. 5 Enrichment of Stable Binders Under Standard versus Heat-Stress Selection DNA Display Enables Stringent Selection Pressure for Thermostable Ligands
Frequently Asked Questions
Q: What is the Veterinary Therapeutic Protein and Peptide DNA Display Platform, and what are its primary applications?
A: Our DNA Display Platform is an advanced in vitro selection technology used to discover high-affinity veterinary therapeutic proteins and peptides. By linking genotype to phenotype via a DNA spacer, it allows for the rapid screening of vast combinatorial libraries. This platform is typically applied in preclinical research to isolate novel antibody fragments, binding proteins, and bioactive peptides tailored for various animal species. For specific library compatibility or customized screening design, we advise consulting our technical support team.
Q: What kinds of input materials or project details are required from clients before initiating a DNA display screening project?
A: To kick off a project, we generally request target protein sequences, known biochemical characteristics, desired target species, and any specific affinity or cross-reactivity requirements you aim to achieve. If you are providing custom DNA libraries or specific templates, detailed concentration, purity, and sequence verification data are also necessary. For assistance with template design or sample submission guidelines, please consult our technical support staff to ensure optimal screening performance.
Q: How does the DNA display platform handle library construction and diversity optimization for veterinary drug discovery?
A: We construct high-diversity DNA libraries tailored to target specific veterinary pathways, utilizing error-prone PCR, site-directed mutagenesis, or synthetic diversification strategies. This maximizes the sequence space exploration to isolate lead candidates with enhanced thermal stability and binding affinity. The exact library size and diversification strategy are customized based on your project goals; please consult our technical support team to determine the best approach for your targets.
Q: What downstream validation and characterization services are available after successful candidate identification via DNA display?
A: Once candidate binders or peptides are identified through our DNA display platform, we offer comprehensive downstream services including recombinant expression, purification, affinity determination via Surface Plasmon Resonance (SPR), and structural characterization. These analyses ensure that the selected leads possess the requisite biophysical properties for preclinical animal trials. To discuss a seamless transition from discovery to functional validation, please consult our technical support team.
BioVenic utilizes in vitro DNA display to discover and develop veterinary therapeutic proteins and peptides for global clients. Our cell-free display technologies support the creation of novel veterinary protein and peptide therapies. For inquiries or more information about our services, please contact us. We are committed to providing expert support and advancing the field of veterinary therapeutic protein and peptide development.
Reference
- Petrov, Dimitar et al. "Flexibility-tuning of dual-display DNA-encoded chemical libraries facilitates cyclic peptide ligand discovery." Nature communications vol. 16,1 3273. 5 Apr. 2025. https://doi.org/10.1038/s41467-025-58507-w. Used under CC BY 4.0. Without Modification.